PEPCLUB.me

Growth Hormone SupportBody CompositionWeight ManagementMetabolic HealthAnti-AgingArticlePremium

Tesamorelin

10mg Vial

2 July 2026Updated 29 August 2026

Tesamorelin

Overview Research0 Mechanism Protocols Safety

Discussions

This is Premium content Premium

Create a free account, then upgrade to Premium or Lifetime to unlock the full research article, mechanism of action, results timeline, dosing protocol, and dose calculator for Tesamorelin.

Create free account Member login

Full range of benefits for Tesamorelin

Reduces visceral abdominal fat in clinical studies of HIV‑associated lipodystrophy

Stimulates endogenous growth hormone release and increases IGF‑1 levels

Decreases hepatic fat content in some controlled trials

May reduce elevated triglyceride levels in affected patients

Lowers waist circumference and abdominal girth measurements

Targets visceral fat while generally preserving subcutaneous fat

Associated with improvements in liver enzymes (eg, ALT) in some studies

Used as a targeted treatment for HIV‑related central fat accumulation

This peptide's combination-safety and interaction data below always stays visible, regardless of membership.

Warning

Important information. The data compiled from scientific literature is provided for educational purposes. Dosage ranges reflect what is reported in studies and do not constitute a recommendation, prescription, or usage guidance. Health decisions should always be made with a qualified professional.

Peptide Interactions

// 12 known interactions

Synergistic(2)Compatible(3)Monitor(3)Avoid(4)

Works exceptionally well with this peptide

GLP-1 receptor agonists (e.g., liraglutide, semaglutide)

May provide additive reductions in visceral adipose tissue and improvements in cardiometabolic risk factors when combined with tesamorelin, though direct trial data are limited.

Metformin

Improves insulin sensitivity and may complement tesamorelin's effects on body composition and metabolic profile, potentially mitigating tesamorelin-associated hyperglycaemia.

All interaction categories

Synergistic (2)

GLP-1 receptor agonists (e.g., liraglutide, semaglutide): May provide additive reductions in visceral adipose tissue and improvements in cardiometabolic risk factors when combined with tesamorelin, though direct trial data are limited.
Metformin: Improves insulin sensitivity and may complement tesamorelin's effects on body composition and metabolic profile, potentially mitigating tesamorelin-associated hyperglycaemia.

Compatible (3)

Antiretroviral therapy (ART): Tesamorelin is indicated for use in people with HIV-associated lipodystrophy and has no consistent clinically significant pharmacokinetic interactions with common ART classes.
Statins: Lipid-lowering HMG-CoA reductase inhibitors can be co-administered without known major pharmacokinetic interactions with tesamorelin and are commonly used concurrently to manage dyslipidaemia.
ACE inhibitors / ARBs: Renin–angiotensin system blockers used for blood pressure control have no established interaction with tesamorelin and are generally neutral in co-administration.

Monitor (3)

Insulin and oral hypoglycaemics (e.g., insulin, sulfonylureas, metformin): Tesamorelin can worsen glucose tolerance and may necessitate monitoring of glucose and adjustment of antidiabetic medication doses.
Recombinant human growth hormone (somatropin): Concurrent GH therapy can produce additive increases in IGF‑1 and related adverse effects, so IGF‑1 and clinical status should be monitored and dosing reviewed.
Levothyroxine (thyroid hormone replacement): GH axis modulation can alter thyroid hormone metabolism and unmask hypothyroidism, so thyroid function tests and levothyroxine dose may need monitoring/adjustment.

Avoid (4)

Somatropin (recombinant human growth hormone): Concomitant use risks excessive GH/IGF‑1 exposure and potential growth‑promoting adverse effects, so combined therapy should be carefully evaluated.
Systemic corticosteroids (e.g., prednisone): Chronic systemic steroids increase insulin resistance and may counteract metabolic benefits of tesamorelin while increasing hyperglycaemia risk.
Thiazolidinediones (e.g., pioglitazone): These agents can promote adipogenesis and peripheral fat accumulation that may attenuate tesamorelin's visceral fat–reducing effects and worsen fluid retention.
Oral estrogen therapy: Oral estrogens can reduce hepatic IGF‑1 production and modify GH responsiveness, potentially attenuating tesamorelin efficacy and altering safety profile.